West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$368.35 USD
+1.81 (0.49%)
Updated May 7, 2024 04:00 PM ET
After-Market: $368.31 -0.04 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
West Pharmaceutical Services (WST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$412.29 | $470.00 | $355.00 | 12.48% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for West Pharmaceutical Services comes to $412.29. The forecasts range from a low of $355.00 to a high of $470.00. The average price target represents an increase of 12.48% from the last closing price of $366.54.
Analyst Price Targets (7 )
Broker Rating
West Pharmaceutical Services currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on seven recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 71.43%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.57 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/13/2024 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
10/28/2023 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
10/26/2023 | William Blair | Matt Larew | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 8 |
Average Target Price | $412.29 |
LT Growth Rate | 7.30% |
Industry | Medical - Dental Supplies |
Industry Rank by ABR | 164 of 252 |
Current Quarter EPS Est: | 1.82 |